

Data quality of OHDSI APAC: CDM Inspection study

2022-05-24 Community call

OHDSI APAC Study Team 4



Background



Figure is recreated from Maxim Moinat slides (21/11/10, at OHDSI community call)



What is this study for?

• Collecting CDM Inspection reports from APAC community

Why this study is needed?

• To check the current status of CDMs, get insights from the CDMs, and improve their data quality

What is the final goal?

- Disclosure of current status of conversion, contents, and data distribution of CDMs of the OHDSI APAC community.
- To provide the basic statistics which can be used as references for future CDM conversion



Study package

- Data sources: CDM databases from OHDSI APAC community
- Collecting inspection reports from each site.
- R package for automatically creating inspection reports.
- Collectibles
 - Number of record, person
 - Number of unique concepts per person
 - Source-CDM mapping ratio
 - Proportion of standard concepts in mapped codes
 - Drug mapping level (granularity)
 - Frequent concept list in each domain
 - Achilles heel result (error / notification / warnings)
 - Sample cohort generation





Study participants







- Specimen
- Visit details
- Visit occurrence



Domain	Mapping codes / source codes	Mapped records / total records	Mapped as standard / Mapped records
	Median [Q1, Q3]	Median [Q1, Q3]	Median [Q1, Q3]
Condition occurrence	97.5 [87.6, 99.6]	99.5 [94.8, 100.0]	100.0 [99.0, 100.0]
Device exposure	56.6 [48.6, 78.2]	75.4 [64.7, 92.2]	79.3 [54.2, 100.0]
Drug exposure	85.0 [74.8, 90.6]	97.0 [96.0, 98.2]	98.3 [97.7, 99.1]
Measurement	50.1 [25.4, 87.1]	97.0 [69.1, 99.7]	100.0 [99.7, 100.0]
Measurement-unit	96.7 [29.7, 100.0]	100.0 [40.8, 100.0]	100.0 [100.0, 100.0]
Measurement-value	13.3 [4.4, 46.0]	7.5 [4.1, 49.4]	100.0 [100.0, 100.0]
Observation	100.0 [98.3, 100.0]	100.0 [93.0, 100.0]	100.0 [100.0, 100.0]
Observation-unit	100.0 [61.1, 100.0]	100.0 [50.4, 100.0]	97.8 [44.4, 100.0]
Observation-value	50.0 [50.0, 100.0]	92.1 [77.8, 100.0]	100.0 [100.0, 100.0]
Procedure occurrence	66.3 [57.5, 97.2]	38.7 [22.4, 95.1]	100.0 [85.1, 100.0]
Visit occurrence	100.0 [100.0, 100.0]	100.0 [100.0, 100.0]	100.0 [100.0, 100.0]

Table 2. Summary result of record mapping to the OMOP concept from common data model databases

Table 3. Vocabulary granularity in drug exposure table

Vocabulary	Classification	N of records	Mapped records / total records, Median [Q1, Q3]
RxNorm (Extension)	Branded Drug	607,710,428	40.1 [1.1, 57.1]
	Clinical Drug	722,805,309	9.4 [2.3, 46.6]
	Quant Branded Drug	266,331,050	17.3 [0.3, 30.6]



Thank you



Chungsoo Kim ted9219@ajou.ac.kr